Loading...
•
Sep 30, 2024
GoodRx Q3 2024 Earnings Report
GoodRx experienced revenue growth and improved profitability, driven by pharma manufacturer solutions and prescription transactions.
Key Takeaways
GoodRx reported an 8% increase in revenue to $195.3 million and a net income of $4.0 million for Q3 2024, compared to a net loss of $38.5 million in the same period last year. The growth was primarily driven by a 77% increase in pharma manufacturer solutions revenue and a 4% increase in prescription transactions revenue.
Revenue and Adjusted Revenue reached $195.3 million.
Net income was $4.0 million, with a net income margin of 2.0%.
Adjusted EBITDA was $65.0 million, resulting in an Adjusted EBITDA Margin of 33.3%.
The company exited the quarter with over 7 million consumers of prescription-related offerings.
Revenue by Segment
Forward Guidance
For the fourth quarter of 2024, GoodRx anticipates revenue and Adjusted Revenue of approximately $200 million and Adjusted EBITDA Margin of about 34%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...